Fortrea

Fortrea Holdings Inc. is a pure-play, publicly traded CRO spun off from LabCorp in 2023, with a mission to accelerate clinical development through tailored, technology-enabled services. The company has established itself as a leader in pharmacovigilance and is at the forefront of integrating diversity and inclusion strategies into trial design. Its core strategy revolves around agile, scalable service delivery models, strategic collaborations, and its proprietary Fortrea Intelligent Technology™ suite to drive operational efficiency and trial success for biopharma and MedTech clients globally.

Fortrea Intelligent Technology™ suite, an integrated operational platform leveraging data analytics, machine learning, and digital tools to optimize site selection, patient recruitment, risk-based monitoring, and trial management for enhanced speed and decision-making.

Fortrea competes with large, full-service CROs like IQVIA, ICON, and Parexel. Its differentiation lies in its agile pure-play structure, deep legacy experience, and first-mover advantage in key regulatory service areas like Diversity Action Plans, though it must continually prove its technology-driven efficiency gains.